Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomized, Open-Label, Multi-center Study to Determine the Safety and Efficacy of Solithromycin in Adolescents and Children With Suspected or Confirmed Community-Acquired Bacterial Pneumonia

NCT02605122 is registered in ClinicalTrials.gov with Melinta Therapeutics, Inc. as lead sponsor.

NCT NCT02605122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02605122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomized, Open-Label, Multi-center Study to Determine the Safety and Efficacy of Solithromycin in Adolescents and Children With Suspected or Confirmed Community-Acquired Bacterial Pneumonia
Lead sponsor
Melinta Therapeutics, Inc.
Phase
Phase 2/3
Overall status
Terminated
Start date
April 30, 2016
Completion date
March 21, 2018
Enrollment
97 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

community-acquired bacterial pneumonia